Hemorrhage risk and clinical features of multiple intracranial arteriovenous malformations

Christine E Boone1, Justin M Caplan2, Wuyang Yang2

  • 1Department of Neuroscience, Johns Hopkins School of Medicine, Baltimore, MD, USA.

Insights

Multiple arteriovenous malformations (MAVM) have a 6.7% annual hemorrhage rate, significantly higher than solitary AVMs. Combined treatment modalities are now preferred for MAVM management.

Area of Science:

  • Neurology
  • Neurosurgery
  • Vascular Malformations

Background:

  • Multiple arteriovenous malformations (MAVM) represent a complex cerebrovascular condition.
  • Understanding the clinical characteristics and hemorrhage risk is crucial for effective management.
  • Previous studies have not fully elucidated the incidence and treatment outcomes specific to MAVM.

Purpose of the Study:

  • To investigate the clinical features, treatment approaches, and annual hemorrhage incidence in patients diagnosed with MAVM.
  • To compare the hemorrhage rate in MAVM patients with that of solitary arteriovenous malformations (AVM).
  • To analyze trends in treatment strategies over time.

Main Methods:

  • A systematic literature search was conducted using PubMed and EMBASE databases.
  • Data from The Johns Hopkins Hospital's AVM database were also included.
  • Descriptive statistics were employed to analyze demographic, clinical, and treatment outcome data for 38 MAVM patients.

Main Results:

  • The annual hemorrhage incidence rate for MAVM patients was 6.7%.
  • Neurological deficit (74%) and hemorrhage (63%) were the most frequent presenting symptoms.
  • Surgical intervention was the primary treatment until 2011, after which multimodal strategies increased to 36%.

Conclusions:

  • MAVM patients exhibit an annual hemorrhage incidence approximately two to three times higher than solitary AVM patients.
  • Multimodal treatment strategies are increasingly favored for managing MAVM.
  • Close patient follow-up is essential due to the potential instability of untreated or partially treated MAVM nidi.